Andrea Sambattit has been appointed new CEO of the Swedish subsidiary of Boehringer Ingelheim.
The last 17 years Sambatti has been working in different fields of the pharmceutical industry, including primary as well as speciaist care with experience from sales, marketing and leadership.
She started her career at Boehringer Ingeheim Brazil in 2009, responsible for oncology and moved to Germany in 2011, with responsibility for the global launch of Ofev (nintedanib).
Andrea Sambatti was appointed Swedish CEo of Boehringer Ingeheim just before christmas and she looks forward to the new job:
“This was exactly what I wanted to do since its a very exciting and dynamic industry, and it enables me to have a positive influence on people’s lives. Swedish Boehringer Ingelheim has an open minded and engaged culture and there is a mixture of different comptencies, experiences and personalities, which is very positive,” says Andrea Sambatti.